ANA Spotlights
Virtual product theater presentations on neurology and neuroscience, brought to you by industry leaders
Please see our featured Spotlights below!
Interested in creating an ANA Spotlights presentation? Learn more about all sponsorship opportunities here or contact the ANA via email at info@myana.org for information.
Disclaimer: The ANA Spotlights videos are paid advertisements and viewers are not to consider the contents as an endorsement of products or services by the ANA. The materials, information or opinions provided during the videos are solely those of the individuals and companies involved and do not necessarily represent those of the ANA.
Optimizing Alzheimer’s Disease Care: The Power of Early Diagnosis in an Evolving Treatment Landscape
2024-10-10
Experience a dynamic session with a focus on equipping neurologists with the latest knowledge to effectively implement emerging Alzheimer’s disease (AD) therapies. Join two neurologists who specialize in AD as they share practical guidance…
Episode Description
Experience a dynamic session with a focus on equipping neurologists with the latest knowledge to effectively implement emerging Alzheimer’s disease (AD) therapies. Join two neurologists who specialize in AD as they share practical guidance on advances in AD and highlight the benefits of collaborative care teams for optimal patient care. Listen in to the engaging discussion on:
- Why early diagnosis is essential and how it can impact patient outcomes.
- The latest advancements in understanding and diagnosing AD.
- Best practices for treatment implementation and provider responsibilities to optimize the patient care paradigm.
Featuring
- Guest: Susan Steen, MD, Axiom Brain Health
- Guest: Jeff Gelblum, MD, FAAN, Nova Southeast College of Medicine
Evolving Perspectives in Alzheimer Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
2024-10-07
Early diagnosis of Alzheimer disease; neuroinflammation as therapeutic target; safety, efficacy of investigational agents targeting neuroinflammation…
Episode Description
Patients with early Alzheimer disease (AD) are not being diagnosed and treated optimally. As few as 20% of Americans with AD are diagnosed, and 50% are exposed to inappropriate medications. Neurologists have an essential role to play in the early diagnosis of AD, leading to earlier interventions (both pharmacologic and nonpharmacologic) to help maintain and improve physical and cognitive functioning. Several clinical trials in individuals “at risk” for AD or with preclinical or prodromal AD are now underway. Underlying mechanisms, which are represented among these trials, include neuroinflammation. There are 3 broad clinical approaches being taken to target neuroinflammation: agents promoting a broad-ranging immunomodulatory effect, agents focusing on the inflammatory signaling cascade, and agents targeting those cells resident in the central nervous system that are involved in neuroinflammation.
This program provides an in-depth review of current state of the art in the early diagnosis of AD through case-based discussion. This engaging satellite symposium also elucidates the role of neuroinflammation as a therapeutic target in AD and highlights safety and efficacy data for investigational agents targeting neuroinflammation.
Featuring
- Guest: Alireza Atri, MD, PhD, Banner Alzheimer’s and Research Institutes
- Guest: Erik S. Musiek, MD, PhD, Washington University School of Medicine
- Guest: Malú Gámez Tansey, PhD, University of Florida College of Medicine